CG0070 Plus Pembrolizumab Shows Preliminary Efficacy in Non-Muscle Invasive Bladder Cancer
All patients achieved a complete response at 3 months.
This content originally appeared on our sister site, Cancer Network.
CG0070 and pembrolizumab yielded promising preliminary findings in a small population of patients with non-muscle invasive bladder cancer who were unresponsive to Bacillus Calmette-Guerin, according to findings from the phase 2 CORE1 trial (NCT04387461).
Investigators found that the combination was well-tolerated with promising efficacy in the study’s population of 9 patients. All patients had achieved a complete response (CR) as of the initial 3-month timepoint in November 2021. All patients who reached additional timepoints (n = 6) maintained a CR at 6 months and 3 maintaALl patients ined a CR at 9 months.
“These preliminary results are exciting,” Roger Li, MD, lead study investigator and urologic oncologist at Moffitt Cancer Center, said in a press release. “If similar trends hold moving forward, we may have a game changer to combat BCG-unresponsive bladder cancer for patients with significant unmet medical need.”
The open label trial has an estimated enrollment of 37 patients. The study’s primary end point is CR with key secondary end points including safety, duration of response, overall survival, and progression-free survival.
WATCH NOW: Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder Cancer
To enroll on the trial, patients were required to have an ECOG performance status of 0 or 1, pathologically confirmed disease, and be unresponsive to BCG therapy. Additionally, patients needed to be ineligible or have refused radical cystectomy and have adequate organ function. Patients who were immunodeficient because of treatment with chronic steroids or immunosuppressants, human immunodeficiency virus, or organ transplant were not eligible for the study. Other exclusion criteria included previous treatment with adenovirus-based therapy or checkpoint inhibitors, clinically significant or active cardiac disease, or active autoimmune disease.
In terms of safety, adverse effects (AEs) were limited to grade 1/2 local genitourinary symptoms and immune-related AEs. These included urinary frequency, bladder spasm, fatigue, chills, autoimmune thyroiditis, blood discharge, dysuria, and flu-like symptoms. Investigators did not report any grade 3 or higher AEs.
“We are excited to announce these preliminary results toward CG0070’s safety, tolerability, and clinical efficacy in patients with bladder cancer unresponsive to BCG who have limited treatment options. We hope to see continued responses as the study progresses, as CG0070’s dual mechanism of action has shown to be highly effective in this difficult-to-treat patient population,” Arthur Kuan, chief executive officer at CG Oncology, concluded.
